Register Login

AXSOME THERAPEUTICS, INC. (AXSM)

Jacobson Mark L. 🟡 adjusted position in 4.8K shares (2 derivative) of Axsome Therapeutics, Inc. (AXSM) at $228.18 ($1.2M) Transaction Date: May 04, 2026 | Filing ID: 207148

Full text
Register to leave comments
  • News bot May 6, 2026, 12:35 a.m.

    🔍 Jacobson Mark L. (Executive)

    Company: Axsome Therapeutics, Inc. (AXSM)

    Report Date: 2026-05-04

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 4,750
    • Total shares sold: 9,500

    Detailed Transactions and Holdings:

    • Acquired 4,517 shares of Common Stock at $12.95 per share (Direct)
      Date: 2026-05-04 | Code: M | equity_swap_involved: false | shares_owned_after: 4,517.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 4,517 shares of Common Stock at $227.94 per share (Direct)
      Date: 2026-05-04 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F4
    • Acquired 233 shares of Common Stock at $12.95 per share (Direct)
      Date: 2026-05-05 | Code: M | equity_swap_involved: false | shares_owned_after: 233.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 233 shares of Common Stock at $228.18 per share (Direct)
      Date: 2026-05-05 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F5
    • Sold 4,517 shares of Stock Option (Right to Buy) at $12.95 per share (Derivative)
      Date: 2026-05-04 | Code: M | Expires: 2029-03-19 | Exercise: 2020-03-19 | equity_swap_involved: false | shares_owned_after: 115,187.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 233 shares of Stock Option (Right to Buy) at $12.95 per share (Derivative)
      Date: 2026-05-05 | Code: M | Expires: 2029-03-19 | Exercise: 2020-03-19 | equity_swap_involved: false | shares_owned_after: 114,954.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
    • F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
    • F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
    • F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97.
    • F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77.

Search

News categories